Treatment of skin GD T cells with anti-NKG2D antibodies impaired lysis of A20 B cell lymphoma cells, but treatment with anti-TCR antibodies had no effect, indicating that NKG2D signaling is sufficient to activate cytotoxicity in skin GD T cells (53). Here, KLRK1 is linked to B-cell non-Hodgkin lymphoma.